| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Nephrectomy | 101 | 2024 | 930 | 9.790 |
Why?
|
| Kidney Neoplasms | 174 | 2024 | 4282 | 9.530 |
Why?
|
| Prostatectomy | 116 | 2023 | 1786 | 8.290 |
Why?
|
| Carcinoma, Renal Cell | 135 | 2024 | 3187 | 8.240 |
Why?
|
| Prostatic Neoplasms | 170 | 2023 | 11101 | 4.970 |
Why?
|
| Prostate-Specific Antigen | 66 | 2023 | 2463 | 2.780 |
Why?
|
| Lymph Node Excision | 20 | 2017 | 1271 | 2.280 |
Why?
|
| Vena Cava, Inferior | 12 | 2023 | 463 | 2.110 |
Why?
|
| Carcinoma, Transitional Cell | 19 | 2010 | 794 | 1.670 |
Why?
|
| Neoplasm Recurrence, Local | 56 | 2021 | 9419 | 1.620 |
Why?
|
| Prostatic Hyperplasia | 20 | 2007 | 516 | 1.560 |
Why?
|
| Urinary Bladder Neoplasms | 26 | 2021 | 2195 | 1.560 |
Why?
|
| Prostate | 23 | 2021 | 1765 | 1.530 |
Why?
|
| Ureteral Neoplasms | 8 | 2008 | 107 | 1.380 |
Why?
|
| Thrombectomy | 9 | 2023 | 676 | 1.370 |
Why?
|
| Neoplasm Staging | 110 | 2017 | 11244 | 1.340 |
Why?
|
| Survival Rate | 85 | 2016 | 12840 | 1.330 |
Why?
|
| Neoplasms, Multiple Primary | 10 | 2008 | 594 | 1.210 |
Why?
|
| Cystectomy | 14 | 2021 | 603 | 1.180 |
Why?
|
| Laparoscopy | 16 | 2024 | 2041 | 1.080 |
Why?
|
| Watchful Waiting | 7 | 2023 | 492 | 0.960 |
Why?
|
| Disease-Free Survival | 51 | 2020 | 6847 | 0.940 |
Why?
|
| Neoplasm Invasiveness | 31 | 2020 | 3620 | 0.940 |
Why?
|
| Aged | 263 | 2023 | 171504 | 0.920 |
Why?
|
| Neoplastic Cells, Circulating | 7 | 2009 | 952 | 0.920 |
Why?
|
| Lymphatic Metastasis | 31 | 2017 | 2914 | 0.920 |
Why?
|
| Neoplasms, Second Primary | 8 | 2010 | 1061 | 0.910 |
Why?
|
| Male | 341 | 2023 | 364719 | 0.880 |
Why?
|
| Ureteroscopy | 7 | 2008 | 140 | 0.870 |
Why?
|
| Cryosurgery | 7 | 2012 | 479 | 0.870 |
Why?
|
| Androgen Antagonists | 13 | 2017 | 1412 | 0.860 |
Why?
|
| Microwaves | 12 | 2001 | 184 | 0.840 |
Why?
|
| Middle Aged | 262 | 2023 | 223492 | 0.820 |
Why?
|
| Venous Thrombosis | 6 | 2023 | 1323 | 0.820 |
Why?
|
| Kidney | 18 | 2018 | 7064 | 0.760 |
Why?
|
| Robotics | 7 | 2014 | 812 | 0.750 |
Why?
|
| Humans | 420 | 2024 | 768166 | 0.750 |
Why?
|
| Urinary Reservoirs, Continent | 4 | 2011 | 29 | 0.720 |
Why?
|
| Warm Ischemia | 5 | 2015 | 59 | 0.710 |
Why?
|
| Aged, 80 and over | 128 | 2020 | 59629 | 0.710 |
Why?
|
| Nomograms | 4 | 2017 | 236 | 0.680 |
Why?
|
| Prognosis | 80 | 2020 | 30010 | 0.680 |
Why?
|
| Renal Veins | 5 | 2017 | 103 | 0.670 |
Why?
|
| Nephrons | 9 | 2015 | 166 | 0.640 |
Why?
|
| Diathermy | 8 | 1998 | 17 | 0.640 |
Why?
|
| Follow-Up Studies | 84 | 2020 | 39348 | 0.630 |
Why?
|
| Urinary Diversion | 4 | 2011 | 134 | 0.630 |
Why?
|
| Postoperative Complications | 30 | 2021 | 15832 | 0.610 |
Why?
|
| Vascular Neoplasms | 3 | 2007 | 167 | 0.610 |
Why?
|
| Antineoplastic Agents, Hormonal | 9 | 2011 | 1536 | 0.600 |
Why?
|
| Survival Analysis | 41 | 2015 | 10101 | 0.590 |
Why?
|
| Treatment Outcome | 90 | 2024 | 65371 | 0.570 |
Why?
|
| Erectile Dysfunction | 5 | 2009 | 437 | 0.570 |
Why?
|
| Kidney Cortex | 2 | 2009 | 168 | 0.560 |
Why?
|
| Adenocarcinoma | 22 | 2008 | 6395 | 0.560 |
Why?
|
| Hyperthermia, Induced | 6 | 2002 | 416 | 0.530 |
Why?
|
| Adenocarcinoma, Clear Cell | 8 | 2005 | 218 | 0.500 |
Why?
|
| Disease Progression | 43 | 2023 | 13671 | 0.500 |
Why?
|
| Urodynamics | 8 | 2011 | 349 | 0.500 |
Why?
|
| Retrospective Studies | 93 | 2024 | 81762 | 0.500 |
Why?
|
| Angiomyolipoma | 4 | 2007 | 189 | 0.490 |
Why?
|
| Lymph Nodes | 11 | 2017 | 3474 | 0.480 |
Why?
|
| Tumor Burden | 9 | 2017 | 1906 | 0.480 |
Why?
|
| Biopsy | 16 | 2023 | 6793 | 0.470 |
Why?
|
| Neoadjuvant Therapy | 5 | 2017 | 2907 | 0.470 |
Why?
|
| Natural Orifice Endoscopic Surgery | 1 | 2015 | 119 | 0.440 |
Why?
|
| Adult | 150 | 2020 | 223646 | 0.430 |
Why?
|
| Prostatic Intraepithelial Neoplasia | 4 | 2017 | 81 | 0.420 |
Why?
|
| Urology | 7 | 2017 | 384 | 0.420 |
Why?
|
| Biopsy, Needle | 12 | 2014 | 1622 | 0.420 |
Why?
|
| Seminal Vesicles | 7 | 2011 | 101 | 0.420 |
Why?
|
| Kidney Pelvis | 6 | 2009 | 191 | 0.420 |
Why?
|
| Urinary Incontinence | 5 | 2010 | 490 | 0.390 |
Why?
|
| Predictive Value of Tests | 33 | 2020 | 15454 | 0.380 |
Why?
|
| Antigens, CD | 13 | 2017 | 4035 | 0.380 |
Why?
|
| Minnesota | 10 | 2011 | 339 | 0.370 |
Why?
|
| Female | 144 | 2021 | 397192 | 0.370 |
Why?
|
| Endoscopy | 4 | 2008 | 1854 | 0.360 |
Why?
|
| Circulatory Arrest, Deep Hypothermia Induced | 1 | 2011 | 82 | 0.360 |
Why?
|
| Glomerular Filtration Rate | 2 | 2017 | 2227 | 0.360 |
Why?
|
| Salvage Therapy | 10 | 2021 | 1273 | 0.350 |
Why?
|
| Chemotherapy, Adjuvant | 13 | 2011 | 3556 | 0.350 |
Why?
|
| Radiotherapy, Adjuvant | 7 | 2014 | 1791 | 0.350 |
Why?
|
| Urine | 3 | 2010 | 362 | 0.340 |
Why?
|
| Adrenal Gland Neoplasms | 4 | 2005 | 735 | 0.340 |
Why?
|
| Renal Artery | 2 | 2009 | 354 | 0.340 |
Why?
|
| BK Virus | 2 | 2020 | 120 | 0.330 |
Why?
|
| Angiolipoma | 1 | 2009 | 12 | 0.330 |
Why?
|
| Embolization, Therapeutic | 2 | 2009 | 1402 | 0.330 |
Why?
|
| Thrombosis | 3 | 2023 | 2957 | 0.320 |
Why?
|
| Retroperitoneal Neoplasms | 3 | 2008 | 335 | 0.320 |
Why?
|
| Bone Neoplasms | 6 | 2011 | 2565 | 0.320 |
Why?
|
| Cystitis | 2 | 2008 | 96 | 0.320 |
Why?
|
| Peripheral Nerves | 2 | 2020 | 490 | 0.310 |
Why?
|
| Ploidies | 15 | 2007 | 287 | 0.310 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 1 | 2015 | 1515 | 0.310 |
Why?
|
| Time Factors | 42 | 2020 | 40218 | 0.310 |
Why?
|
| Angiotensin Receptor Antagonists | 1 | 2015 | 1065 | 0.310 |
Why?
|
| Polyomavirus Infections | 2 | 2020 | 192 | 0.300 |
Why?
|
| Colonic Pouches | 1 | 2009 | 122 | 0.300 |
Why?
|
| Orchiectomy | 5 | 2011 | 466 | 0.300 |
Why?
|
| Obesity, Morbid | 2 | 2016 | 1298 | 0.300 |
Why?
|
| Health Status Indicators | 2 | 2014 | 969 | 0.290 |
Why?
|
| Algorithms | 11 | 2016 | 14164 | 0.290 |
Why?
|
| Extracorporeal Circulation | 1 | 2008 | 181 | 0.290 |
Why?
|
| Tumor Virus Infections | 2 | 2020 | 437 | 0.290 |
Why?
|
| Penis | 2 | 2008 | 209 | 0.290 |
Why?
|
| Brachytherapy | 3 | 2005 | 1220 | 0.280 |
Why?
|
| Kallikreins | 2 | 2020 | 219 | 0.280 |
Why?
|
| Preoperative Care | 7 | 2010 | 2258 | 0.280 |
Why?
|
| Necrosis | 7 | 2010 | 1616 | 0.280 |
Why?
|
| Cohort Studies | 33 | 2023 | 41754 | 0.280 |
Why?
|
| Disease Management | 2 | 2016 | 2536 | 0.280 |
Why?
|
| Osteoporotic Fractures | 1 | 2011 | 417 | 0.270 |
Why?
|
| Combined Modality Therapy | 18 | 2021 | 8542 | 0.260 |
Why?
|
| Ligation | 1 | 2007 | 446 | 0.260 |
Why?
|
| Risk Factors | 44 | 2023 | 74944 | 0.260 |
Why?
|
| Immunocompromised Host | 2 | 2009 | 863 | 0.260 |
Why?
|
| Proportional Hazards Models | 29 | 2016 | 12543 | 0.260 |
Why?
|
| Multivariate Analysis | 21 | 2016 | 12077 | 0.260 |
Why?
|
| Hypogonadism | 2 | 2009 | 805 | 0.250 |
Why?
|
| Risk Assessment | 22 | 2020 | 24315 | 0.250 |
Why?
|
| Cause of Death | 9 | 2010 | 3721 | 0.250 |
Why?
|
| Kidney Diseases | 6 | 2012 | 2100 | 0.250 |
Why?
|
| Urinary Fistula | 1 | 2005 | 44 | 0.250 |
Why?
|
| Receptors, Transforming Growth Factor beta | 1 | 2006 | 304 | 0.250 |
Why?
|
| Flutamide | 2 | 2006 | 95 | 0.240 |
Why?
|
| Neoplasm Metastasis | 12 | 2011 | 4912 | 0.240 |
Why?
|
| von Hippel-Lindau Disease | 2 | 2003 | 154 | 0.240 |
Why?
|
| Urinary Bladder | 3 | 2007 | 1157 | 0.240 |
Why?
|
| DNA, Neoplasm | 11 | 2006 | 1744 | 0.240 |
Why?
|
| Epigenesis, Genetic | 3 | 2017 | 3833 | 0.240 |
Why?
|
| Hematemesis | 1 | 2004 | 22 | 0.240 |
Why?
|
| Radiotherapy, High-Energy | 1 | 2005 | 228 | 0.240 |
Why?
|
| Carcinoma, Embryonal | 1 | 2004 | 36 | 0.240 |
Why?
|
| Tomography, X-Ray Computed | 11 | 2017 | 20760 | 0.230 |
Why?
|
| Urethra | 8 | 2015 | 406 | 0.230 |
Why?
|
| Vena Cava Filters | 1 | 2007 | 270 | 0.230 |
Why?
|
| Duodenal Neoplasms | 1 | 2004 | 114 | 0.220 |
Why?
|
| Receptors, Somatomedin | 1 | 2003 | 57 | 0.220 |
Why?
|
| Epidemiologic Methods | 5 | 2011 | 1328 | 0.220 |
Why?
|
| Von Hippel-Lindau Tumor Suppressor Protein | 1 | 2005 | 304 | 0.220 |
Why?
|
| Venae Cavae | 1 | 2003 | 41 | 0.220 |
Why?
|
| Age Factors | 13 | 2020 | 18412 | 0.210 |
Why?
|
| Perioperative Care | 1 | 2011 | 1043 | 0.210 |
Why?
|
| Renal Insufficiency, Chronic | 1 | 2017 | 2298 | 0.210 |
Why?
|
| Carcinoma | 5 | 2016 | 2332 | 0.210 |
Why?
|
| Catheter Ablation | 4 | 2010 | 2780 | 0.210 |
Why?
|
| Osteoporosis | 2 | 2011 | 1605 | 0.200 |
Why?
|
| Urologic Neoplasms | 3 | 2020 | 314 | 0.200 |
Why?
|
| Intraoperative Complications | 6 | 2015 | 1171 | 0.200 |
Why?
|
| Kaplan-Meier Estimate | 13 | 2020 | 6526 | 0.190 |
Why?
|
| Ischemia | 2 | 2007 | 1900 | 0.190 |
Why?
|
| Kidney Diseases, Cystic | 2 | 2005 | 182 | 0.190 |
Why?
|
| Neoplasms, Hormone-Dependent | 1 | 2004 | 410 | 0.190 |
Why?
|
| Organ Transplantation | 2 | 2009 | 1176 | 0.190 |
Why?
|
| Cold Ischemia | 2 | 2015 | 72 | 0.180 |
Why?
|
| Carcinoma, Papillary | 5 | 2015 | 793 | 0.180 |
Why?
|
| Receptors, Immunologic | 4 | 2009 | 1418 | 0.180 |
Why?
|
| Water | 3 | 2004 | 1421 | 0.180 |
Why?
|
| Patient Selection | 10 | 2012 | 4260 | 0.180 |
Why?
|
| Membrane Glycoproteins | 3 | 2005 | 3711 | 0.180 |
Why?
|
| Biopsy, Fine-Needle | 1 | 2005 | 1135 | 0.180 |
Why?
|
| Molecular Targeted Therapy | 1 | 2012 | 2830 | 0.170 |
Why?
|
| Hot Temperature | 3 | 2001 | 1441 | 0.170 |
Why?
|
| Cholinergic Antagonists | 1 | 2001 | 167 | 0.170 |
Why?
|
| Adenoma, Oxyphilic | 3 | 2010 | 152 | 0.170 |
Why?
|
| Testicular Neoplasms | 2 | 2004 | 806 | 0.170 |
Why?
|
| Urinary Bladder, Neurogenic | 1 | 2001 | 176 | 0.170 |
Why?
|
| Urinary Bladder Neck Obstruction | 2 | 2005 | 82 | 0.160 |
Why?
|
| Neuroectodermal Tumors, Primitive | 1 | 2000 | 137 | 0.160 |
Why?
|
| Laser Coagulation | 1 | 2001 | 334 | 0.160 |
Why?
|
| Heart Neoplasms | 1 | 2003 | 374 | 0.160 |
Why?
|
| Radiation Injuries | 2 | 2014 | 1198 | 0.160 |
Why?
|
| Transurethral Resection of Prostate | 4 | 2004 | 77 | 0.150 |
Why?
|
| DNA Methylation | 5 | 2015 | 4428 | 0.150 |
Why?
|
| Lipoma | 3 | 2008 | 296 | 0.150 |
Why?
|
| Adrenergic alpha-Antagonists | 4 | 2001 | 170 | 0.150 |
Why?
|
| Gene Expression Regulation, Neoplastic | 6 | 2017 | 8647 | 0.150 |
Why?
|
| Receptors, Androgen | 2 | 2004 | 1089 | 0.150 |
Why?
|
| Cystitis, Interstitial | 1 | 1998 | 68 | 0.150 |
Why?
|
| Androgens | 5 | 2011 | 1281 | 0.150 |
Why?
|
| Cardiopulmonary Bypass | 2 | 2015 | 1097 | 0.150 |
Why?
|
| Testosterone | 1 | 2009 | 2491 | 0.150 |
Why?
|
| Magnetic Resonance Imaging, Interventional | 1 | 2019 | 195 | 0.140 |
Why?
|
| Urologic Surgical Procedures | 3 | 2006 | 281 | 0.140 |
Why?
|
| Ki-67 Antigen | 6 | 2009 | 630 | 0.140 |
Why?
|
| Obesity | 3 | 2006 | 13090 | 0.140 |
Why?
|
| Hematuria | 2 | 2017 | 232 | 0.140 |
Why?
|
| Peptides | 3 | 2005 | 4354 | 0.140 |
Why?
|
| Microtubule-Associated Proteins | 4 | 2009 | 1074 | 0.140 |
Why?
|
| Heart Atria | 1 | 2003 | 1361 | 0.140 |
Why?
|
| Reproducibility of Results | 10 | 2019 | 20227 | 0.130 |
Why?
|
| Retroperitoneal Space | 1 | 2017 | 175 | 0.130 |
Why?
|
| Electrocoagulation | 4 | 2001 | 156 | 0.130 |
Why?
|
| Ureter | 2 | 2010 | 364 | 0.130 |
Why?
|
| Lymphocytes, Tumor-Infiltrating | 3 | 2007 | 1105 | 0.130 |
Why?
|
| Ultrasonography, Interventional | 2 | 2019 | 1523 | 0.130 |
Why?
|
| Immunohistochemistry | 16 | 2010 | 11095 | 0.130 |
Why?
|
| Leiomyosarcoma | 1 | 2000 | 426 | 0.130 |
Why?
|
| Metabolic Networks and Pathways | 2 | 2013 | 801 | 0.130 |
Why?
|
| Insulin-Like Growth Factor II | 1 | 2017 | 271 | 0.130 |
Why?
|
| beta-Galactosidase | 1 | 2017 | 574 | 0.130 |
Why?
|
| Ultrasonography, Doppler, Color | 1 | 2017 | 234 | 0.130 |
Why?
|
| Wisconsin | 1 | 2015 | 122 | 0.120 |
Why?
|
| Genomic Imprinting | 1 | 2017 | 326 | 0.120 |
Why?
|
| Length of Stay | 8 | 2016 | 6498 | 0.120 |
Why?
|
| Lung Neoplasms | 3 | 2011 | 13586 | 0.120 |
Why?
|
| Thrombolytic Therapy | 1 | 2004 | 2055 | 0.120 |
Why?
|
| Tissue Array Analysis | 1 | 2017 | 551 | 0.120 |
Why?
|
| Incidence | 9 | 2015 | 21538 | 0.120 |
Why?
|
| Intraoperative Care | 3 | 2010 | 770 | 0.120 |
Why?
|
| Urethral Neoplasms | 1 | 1994 | 37 | 0.120 |
Why?
|
| Lung Diseases | 2 | 2014 | 1944 | 0.120 |
Why?
|
| Quality of Life | 10 | 2014 | 13490 | 0.120 |
Why?
|
| Urothelium | 1 | 2016 | 275 | 0.120 |
Why?
|
| Caspase 3 | 1 | 2017 | 730 | 0.120 |
Why?
|
| Lymphangioleiomyomatosis | 1 | 1996 | 207 | 0.120 |
Why?
|
| Urinary Tract Infections | 2 | 2012 | 804 | 0.110 |
Why?
|
| RNA, Neoplasm | 2 | 2015 | 749 | 0.110 |
Why?
|
| Preoperative Period | 2 | 2015 | 565 | 0.110 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 2 | 2017 | 3800 | 0.110 |
Why?
|
| GRB10 Adaptor Protein | 1 | 2013 | 23 | 0.110 |
Why?
|
| Iatrogenic Disease | 2 | 2009 | 552 | 0.110 |
Why?
|
| Acetyl-CoA Carboxylase | 1 | 2013 | 72 | 0.110 |
Why?
|
| Decision Trees | 1 | 2015 | 508 | 0.110 |
Why?
|
| Mastectomy, Segmental | 1 | 2018 | 974 | 0.110 |
Why?
|
| Angiography | 2 | 2009 | 1597 | 0.110 |
Why?
|
| Ureteral Calculi | 3 | 2003 | 111 | 0.110 |
Why?
|
| Antigens, Neoplasm | 3 | 2015 | 1997 | 0.100 |
Why?
|
| Pentose Phosphate Pathway | 1 | 2013 | 126 | 0.100 |
Why?
|
| Pain, Postoperative | 3 | 2004 | 1765 | 0.100 |
Why?
|
| Pain | 2 | 2007 | 5100 | 0.100 |
Why?
|
| NF-E2-Related Factor 2 | 1 | 2015 | 381 | 0.100 |
Why?
|
| Abdominal Neoplasms | 3 | 2010 | 287 | 0.100 |
Why?
|
| Severity of Illness Index | 5 | 2008 | 15948 | 0.100 |
Why?
|
| Cadherins | 1 | 2017 | 905 | 0.100 |
Why?
|
| Matched-Pair Analysis | 2 | 2011 | 285 | 0.100 |
Why?
|
| Citric Acid Cycle | 1 | 2013 | 234 | 0.100 |
Why?
|
| Chromatin | 2 | 2014 | 2981 | 0.100 |
Why?
|
| Adrenalectomy | 2 | 2005 | 348 | 0.100 |
Why?
|
| Liver Neoplasms | 1 | 2008 | 4362 | 0.100 |
Why?
|
| Registries | 8 | 2011 | 8375 | 0.100 |
Why?
|
| Analysis of Variance | 4 | 2017 | 6229 | 0.100 |
Why?
|
| Gene Regulatory Networks | 1 | 2020 | 1752 | 0.100 |
Why?
|
| Smoking | 2 | 2008 | 9092 | 0.100 |
Why?
|
| Proto-Oncogene Proteins c-met | 1 | 2015 | 564 | 0.100 |
Why?
|
| Randomized Controlled Trials as Topic | 5 | 2017 | 10399 | 0.090 |
Why?
|
| Forecasting | 3 | 2006 | 2945 | 0.090 |
Why?
|
| Soft Tissue Neoplasms | 1 | 2000 | 1164 | 0.090 |
Why?
|
| Adenoma, Chromophobe | 3 | 2005 | 16 | 0.090 |
Why?
|
| Nuclear Proteins | 3 | 2002 | 5804 | 0.090 |
Why?
|
| Reoperation | 4 | 2008 | 4329 | 0.090 |
Why?
|
| Diagnosis, Differential | 4 | 2007 | 13014 | 0.090 |
Why?
|
| Diagnostic Errors | 2 | 1998 | 1281 | 0.090 |
Why?
|
| Surgical Stapling | 1 | 2011 | 98 | 0.090 |
Why?
|
| Body Mass Index | 4 | 2016 | 13053 | 0.090 |
Why?
|
| Microsatellite Repeats | 2 | 2004 | 785 | 0.090 |
Why?
|
| Neoplasm Proteins | 4 | 2007 | 3603 | 0.080 |
Why?
|
| Prospective Studies | 14 | 2018 | 54926 | 0.080 |
Why?
|
| AMP-Activated Protein Kinases | 1 | 2013 | 596 | 0.080 |
Why?
|
| Comorbidity | 6 | 2014 | 10590 | 0.080 |
Why?
|
| Young Adult | 11 | 2017 | 60066 | 0.080 |
Why?
|
| Genome, Human | 3 | 2020 | 4446 | 0.080 |
Why?
|
| Fentanyl | 1 | 1992 | 451 | 0.080 |
Why?
|
| Cell Proliferation | 3 | 2017 | 10474 | 0.080 |
Why?
|
| Carcinoma in Situ | 1 | 2014 | 788 | 0.080 |
Why?
|
| Renal Insufficiency | 1 | 2015 | 812 | 0.080 |
Why?
|
| Antineoplastic Agents | 1 | 2012 | 13676 | 0.080 |
Why?
|
| Italy | 1 | 2011 | 856 | 0.080 |
Why?
|
| Nitrofurantoin | 1 | 2008 | 18 | 0.080 |
Why?
|
| Chromatin Assembly and Disassembly | 1 | 2013 | 633 | 0.080 |
Why?
|
| Genetic Linkage | 2 | 2004 | 2342 | 0.080 |
Why?
|
| Wilms Tumor | 2 | 1991 | 378 | 0.080 |
Why?
|
| Histone-Lysine N-Methyltransferase | 1 | 2013 | 701 | 0.080 |
Why?
|
| Anti-Infective Agents, Urinary | 1 | 2008 | 28 | 0.080 |
Why?
|
| Survival | 2 | 2006 | 160 | 0.080 |
Why?
|
| Equipment Design | 5 | 2007 | 3522 | 0.080 |
Why?
|
| Sarcoma | 3 | 2004 | 1806 | 0.080 |
Why?
|
| Cryotherapy | 1 | 2009 | 164 | 0.080 |
Why?
|
| Virus Integration | 2 | 2020 | 307 | 0.080 |
Why?
|
| Morphine | 1 | 1992 | 658 | 0.080 |
Why?
|
| Sulfones | 2 | 2009 | 448 | 0.080 |
Why?
|
| Pressure | 1 | 2011 | 1172 | 0.070 |
Why?
|
| Anastomosis, Surgical | 1 | 2011 | 991 | 0.070 |
Why?
|
| Specimen Handling | 2 | 2010 | 708 | 0.070 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2020 | 3671 | 0.070 |
Why?
|
| Age Distribution | 2 | 2005 | 2873 | 0.070 |
Why?
|
| Regression Analysis | 3 | 2007 | 6340 | 0.070 |
Why?
|
| Kidney Function Tests | 2 | 2010 | 684 | 0.070 |
Why?
|
| Kidney Transplantation | 3 | 2020 | 4262 | 0.070 |
Why?
|
| Antibiotic Prophylaxis | 1 | 2012 | 640 | 0.070 |
Why?
|
| PTEN Phosphohydrolase | 1 | 2013 | 1120 | 0.070 |
Why?
|
| Purines | 2 | 2009 | 615 | 0.070 |
Why?
|
| Linear Models | 4 | 2011 | 5884 | 0.070 |
Why?
|
| Cadaver | 1 | 2011 | 1363 | 0.070 |
Why?
|
| Hemangioma | 2 | 1993 | 727 | 0.070 |
Why?
|
| Anesthesia, Local | 2 | 2007 | 278 | 0.070 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 3 | 2004 | 11878 | 0.070 |
Why?
|
| Urachus | 1 | 2006 | 18 | 0.070 |
Why?
|
| Etoposide | 3 | 2004 | 639 | 0.070 |
Why?
|
| Catheterization | 2 | 2009 | 1430 | 0.070 |
Why?
|
| Double-Blind Method | 5 | 2007 | 12465 | 0.070 |
Why?
|
| DNA Mutational Analysis | 2 | 2013 | 4120 | 0.070 |
Why?
|
| Apoptosis | 3 | 2017 | 9523 | 0.060 |
Why?
|
| Diet | 1 | 2004 | 8089 | 0.060 |
Why?
|
| Lod Score | 3 | 2004 | 600 | 0.060 |
Why?
|
| Lymphocyte Subsets | 1 | 2007 | 313 | 0.060 |
Why?
|
| Kidney Cortex Necrosis | 1 | 1985 | 6 | 0.060 |
Why?
|
| Mutation | 4 | 2015 | 30238 | 0.060 |
Why?
|
| Anemia | 1 | 2015 | 1514 | 0.060 |
Why?
|
| Sensitivity and Specificity | 9 | 2007 | 14729 | 0.060 |
Why?
|
| History, 21st Century | 1 | 2011 | 1573 | 0.060 |
Why?
|
| Chromosomes, Human, Pair 8 | 1 | 2007 | 452 | 0.060 |
Why?
|
| History, 20th Century | 2 | 2011 | 2766 | 0.060 |
Why?
|
| Bleomycin | 2 | 2004 | 492 | 0.060 |
Why?
|
| Piperazines | 2 | 2009 | 2554 | 0.060 |
Why?
|
| Evaluation Studies as Topic | 1 | 2007 | 1627 | 0.060 |
Why?
|
| Blood Sedimentation | 1 | 2006 | 236 | 0.060 |
Why?
|
| Urinary Tract | 1 | 2008 | 305 | 0.060 |
Why?
|
| Antigens, Nuclear | 2 | 2002 | 183 | 0.060 |
Why?
|
| Adenocarcinoma, Mucinous | 1 | 1989 | 526 | 0.060 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 2013 | 2457 | 0.060 |
Why?
|
| Quality Indicators, Health Care | 1 | 2014 | 1805 | 0.060 |
Why?
|
| Prosthesis Design | 1 | 2011 | 2125 | 0.060 |
Why?
|
| Adipose Tissue | 2 | 2007 | 3329 | 0.060 |
Why?
|
| Tuberous Sclerosis | 4 | 1994 | 1042 | 0.060 |
Why?
|
| Blood Coagulation | 1 | 2010 | 1162 | 0.060 |
Why?
|
| Creatinine | 2 | 2007 | 1918 | 0.060 |
Why?
|
| Escherichia coli Infections | 1 | 2008 | 524 | 0.060 |
Why?
|
| Lidocaine | 1 | 2007 | 546 | 0.060 |
Why?
|
| Histones | 1 | 2015 | 2601 | 0.060 |
Why?
|
| Patient-Centered Care | 1 | 2014 | 1444 | 0.060 |
Why?
|
| Chi-Square Distribution | 1 | 2010 | 3436 | 0.060 |
Why?
|
| Probability | 2 | 2008 | 2479 | 0.060 |
Why?
|
| Palladium | 1 | 2004 | 67 | 0.060 |
Why?
|
| Phosphatidylinositol 3-Kinases | 1 | 2013 | 2885 | 0.060 |
Why?
|
| Gene Expression Profiling | 2 | 2013 | 9538 | 0.060 |
Why?
|
| Repressor Proteins | 1 | 2014 | 2982 | 0.060 |
Why?
|
| Eosine Yellowish-(YS) | 1 | 2003 | 70 | 0.050 |
Why?
|
| Anesthesia, General | 2 | 2008 | 1189 | 0.050 |
Why?
|
| Magnetic Resonance Imaging | 5 | 2021 | 36743 | 0.050 |
Why?
|
| Imaging, Three-Dimensional | 1 | 2016 | 4063 | 0.050 |
Why?
|
| Arteries | 1 | 2008 | 1127 | 0.050 |
Why?
|
| Adrenal Glands | 1 | 2005 | 557 | 0.050 |
Why?
|
| Surgical Instruments | 1 | 2005 | 381 | 0.050 |
Why?
|
| Hemoglobinometry | 1 | 2002 | 35 | 0.050 |
Why?
|
| Inhibitor of Apoptosis Proteins | 3 | 2009 | 200 | 0.050 |
Why?
|
| Medical Oncology | 1 | 2014 | 2346 | 0.050 |
Why?
|
| Germ-Line Mutation | 4 | 2003 | 1885 | 0.050 |
Why?
|
| Radioisotopes | 1 | 2004 | 517 | 0.050 |
Why?
|
| Reagent Strips | 1 | 2002 | 40 | 0.050 |
Why?
|
| Vasodilator Agents | 2 | 2008 | 990 | 0.050 |
Why?
|
| Alprostadil | 1 | 2002 | 86 | 0.050 |
Why?
|
| Laser Therapy | 2 | 2001 | 1107 | 0.050 |
Why?
|
| Proto-Oncogene Proteins c-kit | 1 | 2006 | 725 | 0.050 |
Why?
|
| Receptor, IGF Type 1 | 1 | 2004 | 384 | 0.050 |
Why?
|
| Age of Onset | 4 | 2020 | 3347 | 0.050 |
Why?
|
| Metabolic Diseases | 1 | 2008 | 684 | 0.050 |
Why?
|
| Chromogranins | 1 | 2002 | 160 | 0.050 |
Why?
|
| Phenotype | 2 | 2017 | 16726 | 0.050 |
Why?
|
| Cisplatin | 3 | 2004 | 1660 | 0.050 |
Why?
|
| Apoptosis Regulatory Proteins | 1 | 2007 | 1151 | 0.050 |
Why?
|
| Pain Measurement | 2 | 2007 | 3583 | 0.050 |
Why?
|
| Pulmonary Embolism | 1 | 2015 | 2599 | 0.050 |
Why?
|
| Chromosomes, Human, Pair 1 | 2 | 2002 | 640 | 0.050 |
Why?
|
| Health Status | 1 | 2014 | 4091 | 0.050 |
Why?
|
| Cystoscopy | 2 | 2002 | 128 | 0.050 |
Why?
|
| Palpation | 5 | 2001 | 166 | 0.050 |
Why?
|
| Anesthesia, Spinal | 1 | 2004 | 282 | 0.050 |
Why?
|
| Risk | 3 | 2008 | 9613 | 0.050 |
Why?
|
| MicroRNAs | 2 | 2015 | 3803 | 0.050 |
Why?
|
| Ultrasonography | 6 | 2012 | 6004 | 0.050 |
Why?
|
| Fluorocarbons | 1 | 2006 | 506 | 0.050 |
Why?
|
| Anesthetics, Local | 1 | 2007 | 1005 | 0.040 |
Why?
|
| Blood Loss, Surgical | 2 | 2002 | 642 | 0.040 |
Why?
|
| Sex Distribution | 1 | 2005 | 2278 | 0.040 |
Why?
|
| CpG Islands | 2 | 2015 | 1208 | 0.040 |
Why?
|
| 5-alpha Reductase Inhibitors | 1 | 2001 | 112 | 0.040 |
Why?
|
| Endoribonucleases | 1 | 2002 | 231 | 0.040 |
Why?
|
| Costs and Cost Analysis | 1 | 2006 | 1667 | 0.040 |
Why?
|
| Evidence-Based Medicine | 2 | 2011 | 3706 | 0.040 |
Why?
|
| Markov Chains | 2 | 2000 | 979 | 0.040 |
Why?
|
| Antigens, Viral, Tumor | 1 | 2020 | 153 | 0.040 |
Why?
|
| Chromosome Breakage | 1 | 2020 | 159 | 0.040 |
Why?
|
| Estrogens | 1 | 2007 | 1536 | 0.040 |
Why?
|
| Iodine Radioisotopes | 1 | 2004 | 1034 | 0.040 |
Why?
|
| Kinetics | 1 | 2008 | 6329 | 0.040 |
Why?
|
| Atrophy | 1 | 2005 | 1646 | 0.040 |
Why?
|
| Urination Disorders | 1 | 2001 | 236 | 0.040 |
Why?
|
| Cell Division | 3 | 2002 | 4473 | 0.040 |
Why?
|
| Health Care Surveys | 2 | 2012 | 2434 | 0.040 |
Why?
|
| Nitric Oxide | 1 | 2009 | 2146 | 0.040 |
Why?
|
| Phytotherapy | 1 | 2001 | 298 | 0.040 |
Why?
|
| Confidence Intervals | 4 | 2010 | 2923 | 0.040 |
Why?
|
| Telomerase | 2 | 2002 | 751 | 0.040 |
Why?
|
| Tuberculosis, Cardiovascular | 1 | 1999 | 8 | 0.040 |
Why?
|
| Acute Kidney Injury | 1 | 2012 | 1942 | 0.040 |
Why?
|
| Cost-Benefit Analysis | 3 | 2002 | 5536 | 0.040 |
Why?
|
| Odds Ratio | 6 | 2010 | 9669 | 0.040 |
Why?
|
| Leukocytes, Mononuclear | 1 | 2006 | 1854 | 0.040 |
Why?
|
| Clinical Trials as Topic | 5 | 2005 | 8054 | 0.040 |
Why?
|
| Urinary Incontinence, Stress | 1 | 2001 | 180 | 0.040 |
Why?
|
| Cell Nucleus | 2 | 2003 | 2885 | 0.040 |
Why?
|
| Immunoenzyme Techniques | 1 | 2002 | 1703 | 0.040 |
Why?
|
| Complementary Therapies | 1 | 2003 | 487 | 0.040 |
Why?
|
| T-Lymphocyte Subsets | 1 | 2007 | 1815 | 0.040 |
Why?
|
| Staining and Labeling | 1 | 2003 | 1081 | 0.040 |
Why?
|
| Pedigree | 5 | 2010 | 4539 | 0.040 |
Why?
|
| Transcription Factors | 2 | 2017 | 12168 | 0.040 |
Why?
|
| Clinical Protocols | 1 | 2004 | 1443 | 0.040 |
Why?
|
| Cytoplasm | 1 | 2003 | 1505 | 0.040 |
Why?
|
| CD4-Positive T-Lymphocytes | 2 | 2011 | 4415 | 0.040 |
Why?
|
| Tumor Cells, Cultured | 2 | 2017 | 6124 | 0.040 |
Why?
|
| Job Satisfaction | 1 | 2002 | 548 | 0.040 |
Why?
|
| Clinical Trials, Phase II as Topic | 1 | 2001 | 640 | 0.040 |
Why?
|
| Aneurysm, Infected | 1 | 1999 | 81 | 0.040 |
Why?
|
| Mycobacterium bovis | 1 | 1999 | 148 | 0.040 |
Why?
|
| Multicenter Studies as Topic | 3 | 2004 | 1737 | 0.040 |
Why?
|
| Blood Transfusion | 3 | 2016 | 1309 | 0.040 |
Why?
|
| Carboxypeptidases | 1 | 1998 | 121 | 0.040 |
Why?
|
| Dogs | 2 | 1994 | 3845 | 0.040 |
Why?
|
| Chromosome Mapping | 3 | 2004 | 4620 | 0.040 |
Why?
|
| Genetic Predisposition to Disease | 7 | 2010 | 18065 | 0.040 |
Why?
|
| Solubility | 2 | 2011 | 1083 | 0.040 |
Why?
|
| Transcriptional Activation | 1 | 2004 | 1750 | 0.040 |
Why?
|
| Genetic Variation | 4 | 2007 | 6611 | 0.040 |
Why?
|
| Immunotherapy | 3 | 2005 | 4755 | 0.040 |
Why?
|
| Infusions, Intravenous | 2 | 2012 | 2230 | 0.040 |
Why?
|
| Cyclins | 1 | 2000 | 606 | 0.040 |
Why?
|
| Serotonin | 1 | 2002 | 1043 | 0.040 |
Why?
|
| Calcium | 1 | 2010 | 5792 | 0.040 |
Why?
|
| Postoperative Care | 3 | 2011 | 1480 | 0.040 |
Why?
|
| DNA-Binding Proteins | 1 | 2014 | 9615 | 0.040 |
Why?
|
| Carcinosarcoma | 1 | 1998 | 108 | 0.040 |
Why?
|
| Logistic Models | 4 | 2010 | 13290 | 0.040 |
Why?
|
| Genomics | 1 | 2013 | 5926 | 0.040 |
Why?
|
| Longitudinal Studies | 3 | 2004 | 14783 | 0.030 |
Why?
|
| Hemorrhage | 1 | 2009 | 3467 | 0.030 |
Why?
|
| Hospital Mortality | 1 | 2011 | 5349 | 0.030 |
Why?
|
| Treatment Failure | 5 | 2003 | 2661 | 0.030 |
Why?
|
| Flow Cytometry | 5 | 2008 | 5902 | 0.030 |
Why?
|
| Genome, Viral | 1 | 2020 | 674 | 0.030 |
Why?
|
| Databases, Factual | 2 | 2020 | 8080 | 0.030 |
Why?
|
| Genital Neoplasms, Male | 1 | 1996 | 68 | 0.030 |
Why?
|
| Ileum | 1 | 1998 | 558 | 0.030 |
Why?
|
| In Situ Hybridization, Fluorescence | 1 | 2002 | 2521 | 0.030 |
Why?
|
| BCG Vaccine | 1 | 1999 | 381 | 0.030 |
Why?
|
| Adrenergic beta-Antagonists | 1 | 2001 | 1243 | 0.030 |
Why?
|
| Dysgerminoma | 1 | 1995 | 66 | 0.030 |
Why?
|
| Protein Kinases | 1 | 2003 | 1611 | 0.030 |
Why?
|
| Sex Factors | 2 | 2010 | 10632 | 0.030 |
Why?
|
| United States | 9 | 2014 | 73039 | 0.030 |
Why?
|
| Genes, Dominant | 1 | 1998 | 855 | 0.030 |
Why?
|
| Adolescent | 11 | 2008 | 89169 | 0.030 |
Why?
|
| Gene Expression | 2 | 2005 | 7598 | 0.030 |
Why?
|
| Thoracic Neoplasms | 2 | 2010 | 269 | 0.030 |
Why?
|
| X Chromosome | 1 | 1998 | 819 | 0.030 |
Why?
|
| Models, Statistical | 2 | 2007 | 5107 | 0.030 |
Why?
|
| Oxygen | 1 | 2006 | 4270 | 0.030 |
Why?
|
| Intestines | 1 | 2003 | 1909 | 0.030 |
Why?
|
| Postoperative Period | 3 | 2010 | 1826 | 0.030 |
Why?
|
| Academic Medical Centers | 2 | 2017 | 2784 | 0.030 |
Why?
|
| Genetic Testing | 2 | 2004 | 3591 | 0.030 |
Why?
|
| Managed Care Programs | 1 | 1999 | 939 | 0.030 |
Why?
|
| Anti-Bacterial Agents | 1 | 2012 | 7477 | 0.030 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 2004 | 2954 | 0.030 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2018 | 12252 | 0.030 |
Why?
|
| Decision Support Techniques | 2 | 2000 | 2008 | 0.030 |
Why?
|
| Antigens, Surface | 1 | 1998 | 1617 | 0.030 |
Why?
|
| Signal Transduction | 2 | 2015 | 23645 | 0.030 |
Why?
|
| Lymphangiomyoma | 1 | 1993 | 9 | 0.030 |
Why?
|
| Urography | 1 | 1994 | 316 | 0.030 |
Why?
|
| Ultrasound, High-Intensity Focused, Transrectal | 1 | 2012 | 6 | 0.030 |
Why?
|
| Practice Guidelines as Topic | 1 | 2010 | 7454 | 0.030 |
Why?
|
| Urinary Catheterization | 1 | 1993 | 195 | 0.030 |
Why?
|
| Gonadotropin-Releasing Hormone | 2 | 2011 | 1149 | 0.030 |
Why?
|
| ROC Curve | 1 | 2000 | 3628 | 0.030 |
Why?
|
| Drug Costs | 1 | 2000 | 1195 | 0.030 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 2 | 2011 | 3814 | 0.030 |
Why?
|
| Case-Control Studies | 6 | 2007 | 22291 | 0.020 |
Why?
|
| Self Administration | 1 | 1992 | 386 | 0.020 |
Why?
|
| Kidney Failure, Chronic | 2 | 2020 | 2496 | 0.020 |
Why?
|
| Second-Look Surgery | 1 | 2010 | 27 | 0.020 |
Why?
|
| Enzyme Inhibitors | 1 | 2001 | 3728 | 0.020 |
Why?
|
| Vaginal Neoplasms | 1 | 1991 | 105 | 0.020 |
Why?
|
| Florida | 1 | 1992 | 417 | 0.020 |
Why?
|
| Health Care Costs | 2 | 2000 | 3239 | 0.020 |
Why?
|
| Urinary Bladder Diseases | 1 | 1991 | 166 | 0.020 |
Why?
|
| Vaginal Diseases | 1 | 1991 | 103 | 0.020 |
Why?
|
| Constriction | 1 | 2010 | 168 | 0.020 |
Why?
|
| Delphi Technique | 1 | 2014 | 891 | 0.020 |
Why?
|
| Melanosis | 1 | 1991 | 93 | 0.020 |
Why?
|
| Pelvis | 2 | 2009 | 736 | 0.020 |
Why?
|
| Terminology as Topic | 1 | 1997 | 1542 | 0.020 |
Why?
|
| Testicular Diseases | 1 | 1990 | 72 | 0.020 |
Why?
|
| Tumor Suppressor Proteins | 1 | 2000 | 2810 | 0.020 |
Why?
|
| Culture Media, Conditioned | 1 | 2011 | 521 | 0.020 |
Why?
|
| Light Coagulation | 1 | 1989 | 72 | 0.020 |
Why?
|
| Referral and Consultation | 1 | 2002 | 3620 | 0.020 |
Why?
|
| Image Processing, Computer-Assisted | 1 | 2006 | 9015 | 0.020 |
Why?
|
| Analgesia, Epidural | 1 | 1992 | 332 | 0.020 |
Why?
|
| Molecular Sequence Data | 3 | 2011 | 17622 | 0.020 |
Why?
|
| Animals | 5 | 2017 | 169246 | 0.020 |
Why?
|
| Actuarial Analysis | 1 | 1988 | 370 | 0.020 |
Why?
|
| Polymorphism, Single Nucleotide | 2 | 2007 | 16045 | 0.020 |
Why?
|
| Cell Cycle Proteins | 1 | 2000 | 3445 | 0.020 |
Why?
|
| Societies, Medical | 3 | 2010 | 3968 | 0.020 |
Why?
|
| Nephrostomy, Percutaneous | 1 | 2009 | 76 | 0.020 |
Why?
|
| Pelvic Neoplasms | 1 | 2010 | 250 | 0.020 |
Why?
|
| Fellowships and Scholarships | 1 | 2017 | 1135 | 0.020 |
Why?
|
| Remission Induction | 2 | 2007 | 2410 | 0.020 |
Why?
|
| Homeodomain Proteins | 1 | 2017 | 2429 | 0.020 |
Why?
|
| Cytogenetics | 1 | 2008 | 198 | 0.020 |
Why?
|
| Office Visits | 1 | 1992 | 595 | 0.020 |
Why?
|
| Attitude of Health Personnel | 2 | 2012 | 3929 | 0.020 |
Why?
|
| Sequence Analysis, RNA | 1 | 2015 | 2040 | 0.020 |
Why?
|
| Transplantation Immunology | 1 | 2009 | 537 | 0.020 |
Why?
|
| Lithotripsy | 1 | 1988 | 137 | 0.020 |
Why?
|
| Endoscopes | 1 | 1988 | 169 | 0.020 |
Why?
|
| Drug Evaluation | 1 | 2008 | 642 | 0.020 |
Why?
|
| Prevalence | 3 | 2006 | 15869 | 0.020 |
Why?
|
| Data Collection | 3 | 2002 | 3327 | 0.020 |
Why?
|
| Testis | 1 | 1990 | 783 | 0.020 |
Why?
|
| Observer Variation | 1 | 2012 | 2622 | 0.020 |
Why?
|
| Surgical Procedures, Operative | 1 | 1998 | 1932 | 0.020 |
Why?
|
| Recurrence | 2 | 2010 | 8509 | 0.020 |
Why?
|
| Interleukin-2 Receptor alpha Subunit | 1 | 2007 | 306 | 0.020 |
Why?
|
| Rectum | 2 | 2005 | 900 | 0.020 |
Why?
|
| Cross-Sectional Studies | 3 | 2012 | 26379 | 0.020 |
Why?
|
| Constriction, Pathologic | 1 | 2009 | 1104 | 0.020 |
Why?
|
| Neoplasm, Residual | 1 | 2010 | 1015 | 0.020 |
Why?
|
| Genetic Markers | 2 | 2003 | 2603 | 0.020 |
Why?
|
| Antibodies, Monoclonal | 1 | 2002 | 9263 | 0.020 |
Why?
|
| Heart Arrest | 1 | 2015 | 1516 | 0.020 |
Why?
|
| Exudates and Transudates | 1 | 2005 | 175 | 0.010 |
Why?
|
| Administration, Oral | 1 | 2012 | 4030 | 0.010 |
Why?
|
| Mathematics | 1 | 2006 | 704 | 0.010 |
Why?
|
| Sarcoidosis | 1 | 1990 | 535 | 0.010 |
Why?
|
| Molecular Biology | 1 | 2008 | 573 | 0.010 |
Why?
|
| Consensus | 1 | 2014 | 3212 | 0.010 |
Why?
|
| Europe | 1 | 2011 | 3436 | 0.010 |
Why?
|
| Polymorphism, Genetic | 2 | 2007 | 4249 | 0.010 |
Why?
|
| Cell Hypoxia | 1 | 2006 | 662 | 0.010 |
Why?
|
| Boston | 1 | 2016 | 9374 | 0.010 |
Why?
|
| Scavenger Receptors, Class A | 1 | 2003 | 52 | 0.010 |
Why?
|
| Alleles | 2 | 2007 | 6894 | 0.010 |
Why?
|
| Ureteroscopes | 1 | 2003 | 22 | 0.010 |
Why?
|
| Injections, Spinal | 1 | 2004 | 317 | 0.010 |
Why?
|
| Receptors, Scavenger | 1 | 2003 | 123 | 0.010 |
Why?
|
| Drainage | 1 | 2009 | 1183 | 0.010 |
Why?
|
| Chromogranin A | 1 | 2002 | 47 | 0.010 |
Why?
|
| Statistics, Nonparametric | 1 | 2008 | 2862 | 0.010 |
Why?
|
| Blood Vessels | 1 | 2008 | 1110 | 0.010 |
Why?
|
| England | 1 | 2004 | 533 | 0.010 |
Why?
|
| Cardiovascular Diseases | 1 | 2008 | 15662 | 0.010 |
Why?
|
| Cytodiagnosis | 1 | 2006 | 452 | 0.010 |
Why?
|
| Models, Biological | 2 | 2010 | 9495 | 0.010 |
Why?
|
| Cell Count | 1 | 2006 | 1832 | 0.010 |
Why?
|
| Patient Readmission | 1 | 2016 | 3288 | 0.010 |
Why?
|
| Random Allocation | 1 | 2006 | 2396 | 0.010 |
Why?
|
| Mice, Knockout | 1 | 2017 | 14488 | 0.010 |
Why?
|
| Genes, Regulator | 1 | 2003 | 373 | 0.010 |
Why?
|
| Dilatation | 1 | 2003 | 311 | 0.010 |
Why?
|
| Cell Line, Transformed | 1 | 2003 | 866 | 0.010 |
Why?
|
| Recombinant Proteins | 1 | 2011 | 6514 | 0.010 |
Why?
|
| Neurosecretory Systems | 1 | 2002 | 223 | 0.010 |
Why?
|
| Microscopy, Confocal | 1 | 2007 | 1972 | 0.010 |
Why?
|
| Dyslipidemias | 1 | 2008 | 873 | 0.010 |
Why?
|
| Frameshift Mutation | 1 | 2003 | 392 | 0.010 |
Why?
|
| Drug Resistance, Bacterial | 1 | 2008 | 1063 | 0.010 |
Why?
|
| Body Temperature | 1 | 2004 | 780 | 0.010 |
Why?
|
| Haplotypes | 1 | 2007 | 2722 | 0.010 |
Why?
|
| Cyclic GMP | 1 | 2002 | 394 | 0.010 |
Why?
|
| Cross-Cultural Comparison | 1 | 2004 | 638 | 0.010 |
Why?
|
| RNA, Messenger | 1 | 2015 | 12800 | 0.010 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2012 | 10760 | 0.010 |
Why?
|
| Genes, p53 | 1 | 2003 | 714 | 0.010 |
Why?
|
| Cold Temperature | 1 | 2004 | 791 | 0.010 |
Why?
|
| Rabbits | 1 | 2006 | 4772 | 0.010 |
Why?
|
| Codon, Nonsense | 1 | 2001 | 287 | 0.010 |
Why?
|
| Population Surveillance | 1 | 2010 | 2596 | 0.010 |
Why?
|
| Child | 5 | 2008 | 80917 | 0.010 |
Why?
|
| Private Practice | 1 | 2000 | 154 | 0.010 |
Why?
|
| Forkhead Transcription Factors | 1 | 2007 | 1625 | 0.010 |
Why?
|
| Suture Techniques | 1 | 2004 | 775 | 0.010 |
Why?
|
| Patient Acceptance of Health Care | 1 | 1993 | 3231 | 0.010 |
Why?
|
| Likelihood Functions | 1 | 2002 | 994 | 0.010 |
Why?
|
| Introns | 1 | 2002 | 966 | 0.010 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p27 | 1 | 2000 | 317 | 0.010 |
Why?
|
| Amino Acid Sequence | 1 | 2011 | 13421 | 0.010 |
Why?
|
| Quality Improvement | 1 | 2014 | 3857 | 0.010 |
Why?
|
| Administration, Intravesical | 1 | 1999 | 88 | 0.010 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p21 | 1 | 2000 | 379 | 0.010 |
Why?
|
| Models, Genetic | 2 | 2000 | 3447 | 0.010 |
Why?
|
| Incidental Findings | 1 | 2004 | 698 | 0.010 |
Why?
|
| Mice, Inbred C57BL | 1 | 2017 | 22379 | 0.010 |
Why?
|
| Genotype | 2 | 2007 | 13045 | 0.010 |
Why?
|
| Organ Specificity | 1 | 2003 | 1968 | 0.010 |
Why?
|
| Freezing | 1 | 1999 | 311 | 0.010 |
Why?
|
| Graft Survival | 1 | 2009 | 3887 | 0.010 |
Why?
|
| Immunity | 1 | 2004 | 1003 | 0.010 |
Why?
|
| Intraoperative Period | 1 | 1999 | 513 | 0.010 |
Why?
|
| Canada | 1 | 2004 | 2130 | 0.010 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2005 | 4580 | 0.010 |
Why?
|
| Urinary Retention | 1 | 1998 | 101 | 0.010 |
Why?
|
| Immunosuppressive Agents | 1 | 2011 | 4206 | 0.010 |
Why?
|
| Muscle, Smooth | 1 | 2002 | 931 | 0.010 |
Why?
|
| Epithelium | 1 | 2002 | 1607 | 0.010 |
Why?
|
| Glutamate Carboxypeptidase II | 1 | 1998 | 90 | 0.010 |
Why?
|
| Cyclic AMP | 1 | 2002 | 1470 | 0.010 |
Why?
|
| Models, Economic | 1 | 2002 | 719 | 0.010 |
Why?
|
| Lymphocytes | 1 | 2005 | 2614 | 0.010 |
Why?
|
| Proteinuria | 1 | 2000 | 611 | 0.010 |
Why?
|
| Liver Transplantation | 1 | 2009 | 2401 | 0.010 |
Why?
|
| Up-Regulation | 1 | 2006 | 4146 | 0.010 |
Why?
|
| CD8-Positive T-Lymphocytes | 1 | 2011 | 4648 | 0.010 |
Why?
|
| Urination | 1 | 1998 | 204 | 0.010 |
Why?
|
| Child, Preschool | 3 | 1991 | 42669 | 0.010 |
Why?
|
| Chronic Disease | 1 | 2012 | 9384 | 0.010 |
Why?
|
| Fibrin Fibrinogen Degradation Products | 1 | 1999 | 425 | 0.010 |
Why?
|
| Radiography | 1 | 2007 | 6983 | 0.010 |
Why?
|
| Data Interpretation, Statistical | 1 | 2006 | 2709 | 0.010 |
Why?
|
| Genetic Heterogeneity | 1 | 2000 | 736 | 0.010 |
Why?
|
| Graft Rejection | 1 | 2009 | 4492 | 0.010 |
Why?
|
| Exons | 1 | 2002 | 2394 | 0.010 |
Why?
|
| Reference Values | 1 | 2003 | 4938 | 0.010 |
Why?
|
| Escherichia coli | 1 | 2008 | 4214 | 0.010 |
Why?
|
| Heart Transplantation | 1 | 2009 | 3301 | 0.010 |
Why?
|
| Chemoprevention | 1 | 1997 | 327 | 0.010 |
Why?
|
| Vinblastine | 1 | 1996 | 487 | 0.010 |
Why?
|
| Microcirculation | 1 | 1999 | 1281 | 0.010 |
Why?
|
| Insulin Resistance | 1 | 2008 | 3986 | 0.010 |
Why?
|
| Health Priorities | 1 | 1997 | 380 | 0.010 |
Why?
|
| Polymerase Chain Reaction | 1 | 2003 | 6082 | 0.010 |
Why?
|
| Urologic Diseases | 1 | 1997 | 246 | 0.010 |
Why?
|
| Cell Line, Tumor | 1 | 2011 | 17140 | 0.010 |
Why?
|
| Feasibility Studies | 1 | 2004 | 5315 | 0.010 |
Why?
|
| Ambulatory Surgical Procedures | 1 | 1998 | 452 | 0.010 |
Why?
|
| Safety | 1 | 1998 | 1159 | 0.010 |
Why?
|
| Interferon-alpha | 1 | 1997 | 910 | 0.010 |
Why?
|
| Polycystic Kidney Diseases | 1 | 1994 | 133 | 0.010 |
Why?
|
| Capillaries | 1 | 1996 | 755 | 0.010 |
Why?
|
| Pilot Projects | 1 | 2006 | 8741 | 0.010 |
Why?
|
| Cell Cycle | 1 | 2001 | 2932 | 0.010 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 1 | 1999 | 1406 | 0.010 |
Why?
|
| Melanoma | 1 | 1991 | 5706 | 0.010 |
Why?
|
| Hemoglobins | 1 | 1999 | 1531 | 0.010 |
Why?
|
| Family | 1 | 2003 | 3209 | 0.010 |
Why?
|
| Sequence Analysis, DNA | 1 | 2003 | 4786 | 0.010 |
Why?
|
| Disease Models, Animal | 1 | 1991 | 18349 | 0.010 |
Why?
|
| Drug Therapy, Combination | 1 | 2002 | 6316 | 0.010 |
Why?
|
| Heterozygote | 1 | 1998 | 2798 | 0.010 |
Why?
|
| T-Lymphocytes | 1 | 2009 | 10266 | 0.010 |
Why?
|
| Stents | 1 | 2003 | 3195 | 0.010 |
Why?
|
| Base Sequence | 1 | 2002 | 12421 | 0.010 |
Why?
|
| Transplantation, Autologous | 1 | 1996 | 2120 | 0.010 |
Why?
|
| Interleukin-2 | 1 | 1997 | 1895 | 0.010 |
Why?
|
| Vascular Diseases | 1 | 1999 | 1162 | 0.010 |
Why?
|
| Brain Neoplasms | 2 | 2003 | 9118 | 0.010 |
Why?
|
| Mice | 1 | 2017 | 82029 | 0.010 |
Why?
|
| Internet | 1 | 2002 | 3110 | 0.010 |
Why?
|
| Methotrexate | 1 | 1996 | 1721 | 0.010 |
Why?
|
| Doxorubicin | 1 | 1996 | 2234 | 0.010 |
Why?
|
| Phantoms, Imaging | 1 | 1998 | 2512 | 0.010 |
Why?
|
| Patient Satisfaction | 1 | 2002 | 3488 | 0.010 |
Why?
|
| Survivors | 1 | 1997 | 2381 | 0.000 |
Why?
|
| Infant | 1 | 1987 | 36535 | 0.000 |
Why?
|
| DNA | 1 | 1996 | 7214 | 0.000 |
Why?
|
| Research Design | 1 | 1997 | 6211 | 0.000 |
Why?
|